Download Mobile App

Partner Sites

HospiMedica

Clinical Decision Support Tool Automates CKD Risk Assessment in Primary Care

Noninvasive Brain-Computer Interface Enables Responses in Some Unresponsive ICU Patients

Transcatheter Repair System Gains FDA Approval for Severe Tricuspid Regurgitation

Half-Matched Family Donors Could Expand Transplant Access for Severe Aplastic Anemia

Smart Medical Adhesive Patch Uses Heat to Enable Gentle Removal

New COVID-19 Rapid Antigen Test Can Be Run on Mobile Testing Platform for Lab-Quality Test Results in 15 Minutes

By LabMedica International staff writers
Posted on 08 Jan 2021

A new COVID-19 rapid antigen test that provides lab-quality test results in 15 minutes could offer a frequent, fast, cheap and easy COVID-19 screening solution to help meet the surging demand for tests and relieve the global supply chain.

Nanōmix, Inc.’s (Emeryville, CA, USA) eLab COVID-19 Rapid Antigen test is a low-cost, easy-to-use, point-of-care test that provides results in 15 minutes with lab-quality accuracy. More...

The battery-powered, handheld device utilizes proprietary biosensor and microfluidics technologies to perform an electrochemical detection in a single-use, disposable cartridge. The Nanomix eLab is a mobile platform that can test multiple biomarkers using multiple detection methods from a single patient sample in laboratory or non-laboratory environments - so any location, including rural or remote, can have rapid, lab-quality tests for COVID-19 and a variety of other diseases and conditions. The Nanomix eLab is battery powered, portable, and easy-to-use by non-professionals in a variety of critical applications such as assisted living communities, skilled nursing facilities, emergency medical services, schools, businesses, and remote towns and villages.

The company’s eLab COVID-19 assay has also been selected as a finalist in the XPRIZE Rapid COVID Testing competition. The USD 5 million, six-month competition aims to increase COVID-19 testing capabilities 100-times past the current standard, the level of increase needed to more safely return to everyday activities.

“We are excited to be selected as a finalist in the XPRIZE Rapid COVID Testing,” said David Ludvigson, CEO of Nanomix. “The goals of the competition – to develop frequent, fast, low-cost, and easy-to-use COVID tests – align with our corporate mission. The eLab Rapid COVID Antigen test, together with our eLab Rapid COVID Antibody test, form a complete offering for COVID-19 testing.”

“Fast, affordable, and accessible testing is crucial to containing the COVID-19 pandemic and safely reopening schools, businesses and other vital institutions around the world,” said Anousheh Ansari, CEO of XPRIZE. “XPRIZE Rapid COVID Testing competition is inspiring the best entrepreneurs and scientists to form teams and come together to work towards rapid, affordable COVID-19 testing at scale, and ultimately, getting the world up and running again.”

Related Links:
Nanōmix, Inc.

Visit expo >

Gold Member

SARS-CoV-2 Reactive & Non-Reactive Controls

Qnostics SARS-CoV-2 Typing

βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®

New

Alzheimer's Disease Biomarker Assay

Elecsys Phospho-Tau (217P) Plasma

Fully Automated Urinalysis System

DxU 1800 Fully Automated Urinalysis System

Read the full article by registering today, it's FREE!

Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.

Free digital version edition of LabMedica International sent by email on regular basis
Free print version of LabMedica International magazine (available only outside USA and Canada).
Free and unlimited access to back issues of LabMedica International in digital format
Free LabMedica International Newsletter sent every week containing the latest news
Free breaking news sent via email
Free access to Events Calendar
Free access to LinkXpress new product services
REGISTRATION IS FREE AND EASY!